You are here
Aphios Pharma LLC Announces Reg. CF Private Placement Offering
WOBURN, Mass., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Aphios® Pharma LLC is pleased to announce the launch of a private placement offering in accordance with Regulation Crowdfunding (Reg. CF) adopted by the U.S. Securities and Exchange Commission (SEC) through Netcapital.
This equity crowdfunding offering is selling shares at the price of $1.00 per unit to raise maximum offering proceeds of $1,070,00, the limit of a Reg. CF offering, with a minimum investment of $99 and a maximum investment of $107,000 per investor. Equity investments in private placements are speculative and involve a high degree of risk, and those investors who cannot afford to loose their investment should not invest. We currently anticipate closing this offering prior to November 06, 2018, after which further investments may be limited to high net worth and institutional investors until the Company files for an Initial Public Offering (IPO).
More information on this offering can be found at: https://netcapital.com/companies/aphios
About Aphios Pharma LLC: Aphios® Pharma LLC is dedicated to the discovery, nanotechnology delivery, development and commercialization of cannabis-based drugs for CNS and other debilitating disorders. We will manufacture and utilize pharmaceutical-grade pure natural cannabinoids in stable, bioavailable nanoformulations, following cGMP guidelines of the FDA. These cannabinoid nanoformulations will be used to establish clinical evidence for treating highly unmet CNS disorders such as opioid addiction and pain, epilepsy including childhood epilepsy and multiple sclerosis that are only partially and anecdotally addressed by medical marijuana.
About Netcapital Funding Portal, Inc: Netcapital Funding Portal, Inc ("Netcapital") is registered with the SEC as a funding portal and is a member of the Financial Industry Regulatory Authority, Inc. (FINRA). All Regulation CF offerings are conducted through Netcapital. Netcapital does not give investment advice, endorsement, analysis or recommendations with respect to any securities. All securities listed here are being offered by, and all information included in this document are the responsibility of, the applicable issuer of such securities. Netcapital has not taken any steps to verify the adequacy, accuracy or completeness of any information. Neither Netcapital or its affiliates nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy or completeness of any information in this document or the use of information in this document. For inquiries related to Regulation CF securities activity, contact Netcapital Funding Portal Inc.: email@example.com
Forward-Looking Statements: The information contained herein includes forward-looking statements. These statements relate to future events or to future financial performance, and involve known and unknown risks, uncertainties, and other factors, that may cause actual results to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the company’s control and which could, and likely will, materially affect actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects the current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. No obligation exists to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For More Information Contact:
Trevor P. Castor, Ph.D., CEO